Abstract
The current coronavirus disease 2019 (COVID-19) pandemic has urged the scientific community internationally to find answers in terms of therapeutics and vaccines to control SARS-CoV-2. SARS-CoV-2 is the 7th member of the human coronavirus (CoV) family to be implicated in this zoonotic outbreak. With the global popularity of immunization against COVID-19, reports of vaccine-related adverse events are rapidly growing. Local pain at the injection site is the most prevalent occurrence, as are unusual symptoms such as fever, headache, myalgia, and overall discomfort. Those with COVID-19 and pre-existing cardiovascular disorders (CVDs) are at an increased likelihood of severe morbidity and fatality, and the condition has been related to a number of both direct and indirect CVDs outcomes. As a result of acute coronary syndrome, COVID-19 produces CVDs such as arrhythmias, cardiac arrest, cardiogenic shock, myocarditis, stress-cardiomyopathy, and acute myocardial damage (AMD). Because of underlying chronic comorbidities or impaired immune systems, older persons and adolescents should be particularly cautious about vaccine-related CVDs.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
